Article contents
A clinical comparison of phenelzine and electro-convulsive therapy in the treatment of depressive illness
Published online by Cambridge University Press: 08 February 2018
Extract
The mono-amine oxidase inhibitors, of which phenelzine (“Nardil”) is one example, were introduced for the treatment of depressive illness as a result of the observation that iproniazid, which is a mono-amine oxidase inhibitor, produced euphoria and increased mental alertness in some tuberculous patients to whom it was given. Trials of iproniazid in mental illness were carried out (Loomer et al., 1957; Cesarman, 1959), but it was found to be very liable to give rise to side-effects, being particularly toxic to the liver. Other less toxic mono-amine oxidase inhibitors such as phenelzine, which is chemically related to iproniazid, were later developed.
- Type
- Therapeutic Trials
- Information
- Copyright
- Copyright © Royal College of Psychiatrists, 1962
References
- 10
- Cited by
eLetters
No eLetters have been published for this article.